Saturday 17 October 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue fell 58.5%, EPS fell 107.1%, free cash flow fell 342.0% and total debt rose 20.1%, each against the same quarter a year earlier.
87.57
2.63
−2.92%
Follow BNTX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 6 | 6 | 7 | 3 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 509.50 | 5.19 | 3.59 | 27.07 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 11.89 | 11.02 | 14.24 | 11.10 | 7.48 | 6.85 | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 34.84 | 2.80 | 1.98 | 6.54 | 9.20 | 7.09 |
Altman Z″-Score (non-manufacturers) |
— | 2.23 | 1.90 | 3.67 | 16.50 | 18.17 | 15.68 | 13.65 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 71.94 | 2.60 | 5.35 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (2.79) | 2.56 | 36.50 | (3.72) | (3.11) | (3.14) | (2.74) |
P/Operating CF |
(57.01) | (57.01) | (135.65) | 65.79 | (271.39) | 24.68 | 30.26 | (53.39) | 66.76 |
P/B ratio |
6.61 | 6.61 | 15.73 | 12.25 | 4.47 | 1.71 | 1.23 | 1.30 | 1.06 |
Price to Tangible BV |
8.55 | 8.55 | 20.35 | 13.91 | 4.55 | 1.73 | 1.31 | 1.39 | 1.18 |
EV/Sales |
0.00 | 0.00 | 0.00 | 32.54 | 2.71 | 1.18 | 2.26 | 3.19 | 2.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 3.35 | 1.60 | 9.89 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | (1,164.83) | 57.77 | 1.51 | 1.61 | 42.30 | 12.56 |
EV/FCF |
0.00 | 0.00 | 0.00 | (160.68) | 69.54 | 1.55 | 1.85 | (36.10) | (19.85) |
Quick Ratio |
1.15 | 3.42 | 3.86 | 2.50 | 4.15 | 7.19 | 9.12 | 7.25 | 7.40 |
Current Ratio |
1.18 | 3.56 | 4.05 | 2.75 | 4.33 | 7.43 | 9.43 | 7.45 | 7.54 |
Net Debt/EBITDA |
2.42 | 11.22 | 3.05 | 25.35 | (0.12) | (1.09) | (18.69) | 16.26 | 14.29 |
Debt/Assets |
0.00% | 8.30% | 8.85% | 10.36% | 1.90% | 0.91% | 0.95% | 1.13% | 1.22% |
Debt/Equity |
(1.05) | 0.20 | 0.14 | 0.18 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 |
Asset Turnover |
0.12 | 0.39 | 0.15 | 0.31 | 2.10 | 0.84 | 0.17 | 0.12 | 0.13 |
Operating CF/Net income |
0.61 | 1.21 | 1.11 | (0.89) | 0.09 | 1.44 | 5.77 | (0.31) | (0.40) |
Capex/Depreciation |
0.00 | (3.05) | (2.10) | (2.17) | (2.00) | (2.94) | (3.85) | (1.51) | (1.94) |
Interest Coverage |
(47.33) | (30.44) | (88.80) | (1.27) | 50.09 | 668.93 | 28.89 | (47.97) | (20.13) |
| (79.18%) | (44.25%) | (46.21%) | 1.64% | 155.73% | 56.47% | 4.68% | (3.35%) | (6.01%) | |
| (16.22%) | (14.71%) | (24.10%) | 0.98% | 113.92% | 45.96% | 4.07% | (2.92%) | (5.22%) | |
ROIC |
0.00% | 0.00% | (262.39%) | (19.47%) | 94.38% | 127.38% | 11.02% | (28.51%) | (19.03%) |
Return on Tangible Assets |
(61.78%) | (10.94%) | (34.76%) | 1.18% | 86.40% | 48.18% | 5.11% | (3.86%) | (7.53%) |
Average Days of Receivables |
58.19 | 56.73 | 42.58 | 125.90 | 238.16 | 150.68 | 223.15 | 200.86 | 124.23 |
Research and Development Expense of Revenue |
123.19% | 112.12% | 208.55% | 133.73% | 5.00% | 8.88% | 46.69% | 81.94% | 73.34% |
Selling, General and Administrative Expense of Revenue |
47.83% | 23.03% | 44.45% | 22.51% | 1.77% | 3.14% | 14.60% | 21.77% | 21.76% |
Intangible Assets out of Total Assets |
0.00 | 0.13 | 0.11 | 0.07 | 0.01 | 0.01 | 0.05 | 0.05 | 0.09 |
Share Based Compensation of Revenue |
0.00% | 5.99% | 27.84% | 6.66% | 0.42% | 0.33% | (18.72%) | (1.95%) | 2.82% |
Graham Net Nets |
0.07 | 0.07 | 0.03 | 0.04 | 0.21 | 0.54 | 0.67 | 0.62 | 0.66 |
Graham Number |
0.00 | 0.00 | 0.00 | 4.90 | 253.85 | 284.29 | 92.22 | 0.00 | 0.00 |
Earnings Yield |
(1.12%) | (1.12%) | (0.47%) | 0.20% | 19.26% | 27.82% | 3.69% | (2.62%) | (5.50%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | (0.58%) | 1.39% | 38.50% | 18.68% | (0.96%) | (1.42%) |
Revenue per Share |
7.67 | 0.79 | 0.58 | 2.34 | 92.01 | 74.96 | 17.18 | 12.38 | 13.43 |
Operating CF per Share |
(6.56) | (0.36) | (1.05) | (0.07) | 4.31 | 58.80 | 24.16 | 0.93 | 2.13 |
Capex per Share |
0.00 | (0.42) | (0.38) | (0.41) | (0.73) | (1.57) | (3.17) | (2.03) | (3.48) |
Free Cash Flow per Share |
(6.56) | (0.78) | (1.43) | (0.47) | 3.58 | 57.23 | 20.99 | (1.10) | (1.35) |
Cash per Share |
23.00 | 2.55 | 2.76 | 6.54 | 10.06 | 60.91 | 74.44 | 75.55 | 69.64 |
Shareholders Equity per Share |
(6.56) | 1.65 | 2.61 | 6.66 | 57.67 | 86.85 | 91.07 | 87.37 | 89.99 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(6.56) | 1.65 | 2.61 | 6.66 | 57.67 | 86.85 | 91.07 | 87.37 | 89.99 |
Free Cash Flow |
(59.00) | (148.01) | (301.95) | (111.58) | 874.43 | 13,923.01 | 5,049.90 | (263.38) | (326.41) |
Working Capital |
35.00 | 381.27 | 472.65 | 1,211.85 | 13,712.96 | 19,988.27 | 18,893.50 | 17,616.92 | 15,844.46 |
Capital Expenditures |
(65.00) | (79.30) | (79.59) | (96.19) | (178.17) | (382.14) | (763.56) | (488.14) | (842.33) |
Net Current Asset Value |
(283.00) | 74.37 | 286.72 | 822.60 | 13,174.06 | 19,700.74 | 18,146.82 | 16,972.63 | 15,140.62 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 3.36 | 1.62 | 12.52 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.53 | 0.65 | 0.17 | 0.01 | 0.02 | 0.18 | 0.16 | 0.26 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 3.48 | 2.72 | 36.18 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.10 | 0.19 | 0.36 | 0.17 | 0.23 | 0.20 | 0.24 | 0.32 | 0.35 |
Cash ROIC |
(28.10%) | (17.10%) | (24.85%) | (3.30%) | 5.18% | 38.49% | 12.61% | (0.67%) | (0.84%) |
Accounts Receivable Turnover |
3.14 | 8.76 | 6.47 | 5.40 | 3.03 | 1.64 | 0.82 | 1.43 | 2.37 |
Accounts Payable Turnover |
0.40 | 0.29 | 0.54 | 0.97 | 22.50 | 15.61 | 2.17 | 1.39 | 1.36 |
Inventory Turnover |
3.38 | 2.52 | 1.95 | 1.57 | 10.32 | 5.97 | 1.53 | 1.69 | 3.36 |
Average Days of Payables |
1,045.23 | 1,112.36 | 430.95 | 629.25 | 20.06 | 24.87 | 215.42 | 287.73 | 304.20 |
Days of Inventory on Hand |
99.55 | 154.34 | 246.44 | 394.45 | 63.00 | 53.57 | 217.67 | 191.03 | 62.96 |
Average Receivables |
22.00 | 17.21 | 18.80 | 102.11 | 7,419.65 | 11,089.14 | 5,027.99 | 2,082.57 | 1,371.67 |
Average Payables |
55.50 | 56.14 | 36.12 | 69.90 | 153.07 | 202.17 | 299.09 | 422.43 | 533.46 |
Average Inventory |
6.50 | 6.42 | 9.98 | 43.19 | 333.88 | 528.84 | 425.15 | 346.85 | 215.90 |
Average Assets |
598.00 | 385.59 | 832.27 | 1,770.96 | 10,688.99 | 21,628.14 | 24,713.29 | 24,639.56 | 24,628.65 |
Average Common Equity |
122.50 | 128.16 | 434.02 | 1,059.89 | 7,819.25 | 17,601.01 | 21,521.36 | 21,458.45 | 21,377.51 |
Columns are period end dates